Alaunos Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $10.0K | $5.0K | $2.9M | $398.0K | $0 | $146.0K | $15.9M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $1.4M | $362.0K | $16.3M | $25.0M | $49.6M | $52.7M | $34.1M | $45.1M |
| SG&A Expense | $2.9M | $4.5M | $12.2M | $13.1M | $27.6M | $27.7M | $19.9M | $14.8M |
| Operating Income | $-4.2M | $-4.8M | $-34.3M | $-35.1M | $-77.5M | $-80.4M | $-53.9M | $-53.5M |
| Operating Margin | -84,500.0% | -48,120.0% | -685,340.0% | -1,201.4% | -19,484.7% | — | -36,921.9% | -336.4% |
| Interest Expense | — | — | $1.9M | $3.2M | $1.2M | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | — | — | — | — | — | — | — |
| Net Income | $-4.2M | $-4.7M | $-4.7M | $-37.7M | $-78.8M | $-80.0M | $-53.1M | $-54.3M |
| Net Margin | -83,520.0% | -46,790.0% | -93,580.0% | -1,291.2% | -19,786.7% | — | -36,381.5% | -341.7% |
| EPS (Basic) | $-2.20 | $-2.92 | $-21.97 | $-2.61 | $-0.37 | $-0.38 | $0.96 | $-0.53 |
| EPS (Diluted) | $-2.20 | $-2.92 | $-21.97 | $-2.61 | $-0.37 | $-0.38 | $0.96 | $-0.53 |
| Shares Outstanding (Basic) | 1.9M | 1.6M | 1.6M | 14.5M | 214.4M | 209.6M | 143.5M | 136.9M |
| Shares Outstanding (Diluted) | 1.9M | 1.6M | 1.6M | 14.5M | 214.4M | 209.6M | 143.7M | 136.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |